Doximity
DOCS
$24.80
-6.73%
Doximity, Inc. operates a digital platform connecting healthcare professionals, offering tools for collaboration, medical news, career management, and telehealth, with revenue derived from marketing, hiring, and workflow solutions. As a leading healthcare information services provider, it holds a dominant position in the U.S. physician network, with over 80% of physicians as members, distinguishing it as a niche platform with high engagement. The current investor narrative centers on the company's AI-driven growth initiatives, which have recently shown promising returns and sparked a significant post-earnings rally, while also facing scrutiny over revenue growth deceleration and competitive pressures in the digital health space.…
DOCS
Doximity
$24.80
Related headlines
Investment Opinion: Should I buy DOCS Today?
Rating: Hold. Doximity is a high-quality company with a dominant niche, but the stock's recent volatility and growth deceleration warrant caution. The analyst consensus is Hold with an average target of $29.11, implying 17.4% upside from the current price of $24.80. The thesis is that AI-driven growth could re-accelerate, but the market is still skeptical given the past year's decline.
Sign up to view all
DOCS 12-Month Price Forecast
The AI assessment is cautiously bullish, as Doximity's AI investments are showing promising returns with 10x unit economics, driving a recent stock surge. However, the medium confidence reflects the uncertainty around sustaining this momentum given the past year's decline. Key factors include the strong gross margins and forward valuation, which provide a margin of safety. If AI-driven growth continues to accelerate, the stance would upgrade to high confidence bullish; conversely, any signs of AI monetization stalling would shift to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $29.11 and implied upside of +17.4% versus the current price.
Average Target
$29.11
0 analysts
Implied Upside
+17.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $47
Analyst target range
The target price range spans from $18.00 (low) to $47.00 (high), reflecting significant uncertainty. The high target assumes successful AI monetization and accelerated growth, while the low target prices in potential margin compression and competitive losses. Recent institutional actions show a mix of upgrades and neutral stances, with Canaccord Genuity upgrading from Hold to Buy in February, while JP Morgan moved from Underweight to Neutral, suggesting a cautiously improving sentiment. The wide spread between low and high targets underscores the market's divergent views on Doximity's future prospects.
Bulls vs Bears: DOCS Investment Factors
Doximity presents a mixed picture: strong fundamentals with high margins, dominant market position, and AI-driven growth potential, but offset by severe stock price decline, decelerating revenue growth, and valuation concerns. The bull case is supported by the recent AI-driven rally and attractive forward valuation, while the bear case is anchored in growth deceleration and high volatility. Currently, the bull case has slightly stronger evidence given the recent earnings beat and AI momentum, but the key tension lies in whether AI can sustain revenue growth acceleration to justify the valuation. If AI monetization continues to deliver, the stock could re-rate higher; otherwise, growth concerns will likely cap upside.
Bullish
- AI-driven growth acceleration: Doximity's AI investments are paying off with superior performance and 10x unit economics, as highlighted in recent news. This has sparked a significant post-earnings rally, with the stock surging 30% after the latest earnings report, indicating strong market conviction in the AI narrative.
- High gross margins and profitability: The company maintains a gross margin of 89.9% and a net margin of 30.4%, reflecting a highly scalable business model. Operating margin of 33.3% and positive free cash flow of $311.5 million TTM underscore efficient operations and strong cash generation.
- Dominant market position: With over 80% of U.S. physicians as members, Doximity holds a dominant niche in the healthcare professional network. This high engagement base provides a competitive moat and recurring revenue potential, as evidenced by subscription revenue of $175.4 million in Q3 FY2026.
- Attractive forward valuation: The forward PE of 15.99x is significantly lower than the trailing PE of 22.19x, indicating expected earnings growth. This valuation is reasonable for a company with 9.76% YoY revenue growth and a 30%+ net margin, suggesting potential upside if growth sustains.
Bearish
- Severe stock price decline: The stock has fallen 60.97% over the past year, trading at $24.80, only 32.4% of its 52-week range. This reflects persistent bearish sentiment and a significant loss of investor confidence, with the stock still down 42.7% YTD despite a recent rally.
- Revenue growth deceleration: While Q3 FY2026 revenue grew 9.76% YoY, this is a sharp slowdown from earlier double-digit growth rates. The May 2026 earnings report highlighted a 'sharp slowdown in future revenue growth,' causing a stock plunge, indicating that growth concerns remain a key overhang.
- High valuation relative to growth: Despite the forward PE of 15.99x, the PEG ratio is -1.89, reflecting negative earnings growth expectations. The PS ratio of 6.76x is elevated for a company with single-digit revenue growth, suggesting the market may be pricing in overly optimistic AI-driven expansion.
- Competitive and regulatory risks: The digital health space is competitive, with larger tech companies and specialized platforms vying for physician engagement. Regulatory changes in healthcare marketing and data privacy could also impact Doximity's advertising-based revenue model, posing risks to growth.
DOCS Technical Analysis
Doximity's stock has experienced a severe downtrend over the past year, with a 1-year price change of -60.97%, currently trading at $24.80, which is only 32.4% of its 52-week range (low $17.15, high $76.51). This positioning near the lower end of the range suggests a potential value opportunity, but also reflects persistent bearish sentiment and a falling knife risk. The stock's beta of 1.212 indicates higher volatility than the market, amplifying both downside and upside moves.
Beta
1.21
1.21x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$77
Price range past year
Annual Return
-61.0%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | +11.4% | +4.5% |
| 3m | +30.7% | +5.1% |
| 6m | -0.9% | +13.7% |
| 1y | -61.0% | +20.6% |
| ytd | -42.7% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Doximity's revenue trajectory shows robust growth, with the latest quarter (Q3 FY2026) reporting revenue of $185.05 million, a 9.76% YoY increase, and a sequential acceleration from $168.53 million in Q2. The company's subscription revenue, which constitutes the majority at $175.38 million, is driving this growth, while service revenue remains a smaller component. This growth trend, though decelerating from earlier double-digit rates, indicates a resilient demand for its platform, supported by a 90% gross margin.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+9.8%
YoY Comparison
Gross Margin
89.9%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given Doximity's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 22.19x, while the forward PE is 15.99x, indicating the market expects earnings growth. The gap between trailing and forward PE suggests an anticipated improvement in profitability, likely driven by AI-driven efficiencies and scale.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~104x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include Doximity's reliance on continued revenue growth to justify its valuation, with Q3 FY2026 revenue growth of 9.76% YoY, down from earlier double-digit rates. The company's net margin of 30.4% is strong, but any margin compression from increased AI investments or competition could pressure earnings. The balance sheet is solid with minimal debt (D/E 0.01) and high liquidity (current ratio 6.09), reducing financial distress risk, but the stock's high beta (1.212) and 76% max drawdown highlight significant market risk.
FAQ
The key risks for DOCS are: 1) Financial risk: Revenue growth deceleration, with Q3 FY2026 growth of 9.76% YoY, could pressure the stock if it slows further. 2) Competitive risk: The digital health space is competitive, and larger players could erode Doximity's market share. 3) Macro risk: With a beta of 1.212, the stock is sensitive to market swings, and rising interest rates could compress tech valuations. 4) Company-specific risk: AI investments may not yield expected returns, as seen in the May 2026 earnings drop when growth slowed. The most severe risk is a combination of these factors leading to a decline toward the 52-week low of $17.15, representing a 30.8% downside from the current price.
The 12-month forecast for DOCS is mixed, with a base case target of $25-30 (50% probability), a bull case of $35-47 (30% probability), and a bear case of $18-22 (20% probability). The base case assumes revenue growth stabilizes at 8-10%, while the bull case relies on AI-driven acceleration. The bear case reflects competitive or execution risks. The most likely scenario is the base case, with the stock trading around the analyst average target of $29.11. Key factors to watch are the next earnings report and AI adoption metrics.
DOCS appears fairly valued to slightly undervalued based on forward metrics. The forward PE of 15.99x is below the trailing PE of 22.19x, indicating expected earnings growth. The PS ratio of 6.76x is high for a company with 9.76% revenue growth, but the 89.9% gross margin and 30.4% net margin justify a premium. Compared to its own history, the stock is trading near the lower end of its valuation range, suggesting it may be undervalued relative to its past. However, the negative PEG ratio (-1.89) reflects concerns about future growth, so the market is pricing in some risk. Overall, the valuation is reasonable if AI-driven growth materializes, but not a clear bargain.
DOCS is a good buy for investors with a long-term horizon and a tolerance for volatility, given its dominant market position and AI-driven growth potential. The stock trades at a forward PE of 15.99x, which is reasonable relative to its 30% net margin, and the analyst average target of $29.11 implies 17.4% upside. However, the stock has been highly volatile, with a 60.97% decline over the past year, and revenue growth is decelerating. The biggest risk is that AI monetization fails to sustain growth, leading to further downside toward the 52-week low of $17.15. For risk-averse investors, waiting for more evidence of sustained growth might be prudent.
DOCS is better suited for long-term investment given its growth potential and high volatility. The stock has a beta of 1.212, making it prone to sharp swings, which is risky for short-term traders. However, the company's dominant market position and AI initiatives could drive significant value over 3-5 years. The lack of dividends and high reinvestment needs suggest a growth-oriented profile. For long-term investors, a minimum holding period of 3 years is recommended to ride out volatility and allow AI-driven growth to materialize. Short-term traders might find opportunities in the stock's volatility, but the risk of further declines is high.